©  2021 Point of Care Network, LLC. All Rights Reserved.
4 Campus Drive, Suite 302 Parsippany, NJ 07054

Evolving the Paradigm in Severe 

Hypoglycemia Management

Join us for this educational webinar

Register now for a discussion on Evolving the Paradigm in Severe Hypoglycemia Management.

Davida F. Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner
Detroit, MI 

In the event that you are not able to attend this webinar, we recommend that you still register.  As a registrant, you will receive future On-Demand access to the recording of the broadcast.

This event is not eligible for CME credit. This event complies with PhRMA guidelines. Attendance is limited to healthcare professionals.

By submitting this form, you acknowledge and agree that you are “opted-in” to the broadcast and POCN+ and expressly consent to the collection and use of your information as described in our Terms of Use and Privacy Policy statements. 

To review our legal terms of use, please click here

To view our privacy policy, terms & conditions, and cookie policy, please click here.

Register for the Webinar

GVOKE is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 2 years and above.

GVOKE is contraindicated in patients with pheochromocytoma, insulinoma, and known hypersensitivity to glucagon or to any of the excipients in GVOKE. Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension.

Warnings and Precautions
GVOKE is contraindicated in patients with pheochromocytoma because glucagon may stimulate the release of catecholamines from the tumor. If the patient develops a dramatic increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure. 

In patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, GVOKE administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. GVOKE is contraindicated in patients with insulinoma. If a patient develops symptoms of hypoglycemia after a dose of GVOKE, give glucose orally or intravenously. 

Allergic reactions have been reported with glucagon. These include generalized rash, and in some cases, anaphylactic shock with breathing difficulties and hypotension. GVOKE is contraindicated in patients with a prior hypersensitivity reaction. 

GVOKE is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia, may not have adequate levels of hepatic glycogen for GVOKE administration to be effective. Patients with these conditions should be treated with glucose. 

Necrolytic migratory erythema (NME), a skin rash commonly associated with glucagonomas, has been reported postmarketing following continuous glucagon infusion and resolved with discontinuation of the glucagon. Should NME occur, consider whether the benefits of continuous glucagon infusion outweigh the risks. Glucagon administered to patients with glucagonoma may cause secondary hypoglycemia.

Adverse Reactions
Most common (≥5%) adverse reactions associated with GVOKE are nausea, vomiting, injection site edema (raised 1 mm or greater), and hypoglycemia.

Drug Interactions
Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE. In patients taking indomethacin, GVOKE may lose its ability to raise blood glucose or may even produce hypoglycemia. GVOKE may increase the anticoagulant effect of warfarin. 

Please see the Full Prescribing Information for Gvoke HypoPen.

their associated logos are trademarks of Xeris Pharmaceuticals, Inc.

Copyright © 2021 Xeris Pharmaceuticals, Inc.  All rights reserved.  US-GVK-20-00183 01/21

February 24, 2021 - 6:30 PM ET

  • Consider the serious issue of severe hypoglycemia in diabetes, including its prevalence and impact on affected individuals and their glycemic management
  • Discuss how emerging standards of care for severe hypoglycemia can help overcome the limitations of earlier guidelines
  • Recognize administration challenges of existing emergency glucagon kits
  • Review data supporting the safety and efficacy of the first autoinjector for the treatment of severe hypoglycemia:  Gvoke HypoPen® (glucagon injection)
  • Integrate the insights from the webinar into an action plan for the identification and management of patients at risk of severe hypoglycemia 

Meeting Objectives